Exploring Akero Therapeutics, Inc. (AKRO) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Akero Therapeutics, Inc. (AKRO) and, more importantly, why? As of April 2025, 438 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 85,843,156 shares. With the share price standing at $37.60 as of April 14, 2025, a significant 73.11% increase from $21.72 on April 15, 2024, understanding the motivations behind these investments could unlock valuable insights. Are these investors banking on the potential of Akero's metabolic disease treatments, or are other factors at play? Read on to delve into the investor profile of Akero Therapeutics and discover the driving forces behind their decisions.

Akero Therapeutics, Inc. (AKRO) Who Invests in Akero Therapeutics, Inc. (AKRO) and Why?

Understanding the investor profile of Akero Therapeutics, Inc. (AKRO) involves examining the diverse range of entities and individuals who hold shares in the company, as well as their motivations for investing. These investors typically include retail investors, institutional investors, and hedge funds, each with their own investment strategies and objectives.

Key Investor Types:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. They may be attracted to Akero Therapeutics, Inc. (AKRO) due to its growth potential in the biotechnology sector, particularly if they believe in the company's pipeline of drug candidates.
• Institutional Investors: These include entities such as mutual funds, pension funds, and insurance companies. Institutional investors often have a longer-term investment horizon and may be drawn to Akero Therapeutics, Inc. (AKRO)'s potential for long-term growth and its position in addressing unmet medical needs.
• Hedge Funds: These are investment partnerships that may employ a variety of strategies, including long-term investing, short-term trading, and event-driven investing. Hedge funds may invest in Akero Therapeutics, Inc. (AKRO) based on its perceived undervaluation, potential for short-term gains, or strategic opportunities such as mergers or acquisitions.

Investment Motivations:

Several factors attract investors to Akero Therapeutics, Inc. (AKRO):

• Growth Prospects: The biotechnology industry offers significant growth opportunities, particularly for companies developing innovative therapies for diseases with unmet medical needs. Akero Therapeutics, Inc. (AKRO)'s pipeline of drug candidates targeting liver diseases may attract investors seeking high-growth potential.
• Market Position: A company's competitive positioning within its industry can influence investor interest. If Akero Therapeutics, Inc. (AKRO) has a strong market position or a unique technology platform, it may be more attractive to investors.

Investment Strategies:

Investors in Akero Therapeutics, Inc. (AKRO) may employ various investment strategies, depending on their risk tolerance and investment objectives:

• Long-Term Holding: Some investors may adopt a long-term holding strategy, focusing on the company's long-term growth potential and holding shares for an extended period. This strategy is common among institutional investors and those who believe in the company's long-term prospects.
• Short-Term Trading: Other investors may engage in short-term trading, seeking to profit from short-term price fluctuations in the company's stock. This strategy is more common among hedge funds and day traders.
• Value Investing: Value investors look for companies that they believe are undervalued by the market. They may invest in Akero Therapeutics, Inc. (AKRO) if they believe the company's stock price is below its intrinsic value.

For additional background information, you might find this resource helpful: Akero Therapeutics, Inc. (AKRO): History, Ownership, Mission, How It Works & Makes Money

Akero Therapeutics, Inc. (AKRO) Institutional Ownership and Major Shareholders of Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics, Inc. (AKRO) has a significant institutional ownership, reflecting the interest and investment from various financial institutions and funds. As of April 2025, a substantial portion of Akero Therapeutics' shares are held by institutional investors.

According to recent data, 438 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 85,843,156 shares. This indicates a strong institutional presence in the company.

Here’s a detailed look at the top institutional investors and their shareholdings in Akero Therapeutics, Inc. (AKRO) based on the latest filings:

• Wellington Management Group LLP: Holds 7,376,961 shares, representing approximately 9.27% ownership.
• RTW Investments LP: Holds 6,859,823 shares, accounting for about 8.62% of the ownership.
• Versant Venture Capital VI LP: Holds 6,749,283 shares, accounting for about 8.48% of the ownership.
• Janus Henderson Group PLC: Possesses 6,034,239 shares, which is around 7.58% ownership.
• BlackRock, Inc.: Holds 5,924,183 shares, representing approximately 7.44% of the company.
• General Atlantic LLC: Holds 5,233,989 shares, accounting for about 6.57% of the ownership.
• Price T Rowe Associates Inc: Holds 4,321,972 shares, representing approximately 5.43% of the company.
• Vanguard Group Inc: Holds 3,704,411 shares, accounting for about 4.65% of the ownership.

These major shareholders play a crucial role in the company's stock performance and strategic direction.

Here is a table summarizing the top institutional holders:

Examining recent transactions and changes in ownership provides insights into the confidence and strategies of these major investors.

Recent data indicates some shifts in institutional ownership. For example, SG Americas Securities LLC reported holding 1,155,787 shares as of April 15, 2025, reflecting a significant increase of +93.3%. Similarly, Woodline Partners LP increased their holdings by 29.9%, now possessing 379,967 shares.

Conversely, some institutions have reduced their stakes. For instance, Rafferty Asset Management LLC decreased their holdings by -19.7%, holding 72,604 shares. Redmile Group LLC also reduced their position by -11.0%, with 1,235,209 shares.

Overall, institutional investors play a vital role in Akero Therapeutics' stock price and strategic decisions. Their investment activities can significantly influence market sentiment and the company's access to capital.

You might also be interested in reading more about Akero Therapeutics, Inc. (AKRO)'s financial health: Breaking Down Akero Therapeutics, Inc. (AKRO) Financial Health: Key Insights for Investors

Akero Therapeutics, Inc. (AKRO) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Akero Therapeutics, Inc. (AKRO) provides valuable insights into the company's stability, growth potential, and strategic direction. Analyzing who is investing, and their recent activity, can offer clues about market sentiment and future performance. Here’s a look at some key aspects of Akero Therapeutics, Inc. (AKRO)'s investor landscape.

While specific real-time data on all Akero Therapeutics, Inc. (AKRO) investors and their direct influence can fluctuate, examining publicly available information and typical investor behaviors in similar companies offers a reasonable understanding.

Notable Investors

Institutional investors, venture capital firms specializing in biotechnology, and potentially some individual activist investors could be key players in Akero Therapeutics, Inc. (AKRO). Identifying specific funds or individuals with significant holdings can be done by reviewing the company's SEC filings (e.g., 13F filings) which disclose the holdings of institutional investment managers.

Investor Influence

Large institutional investors often have considerable influence through:

• Voting Rights: Significant shareholders can influence the election of board members and vote on important company matters such as mergers, acquisitions, and executive compensation.
• Engagement with Management: Major investors often engage directly with the company's management to discuss strategy, performance, and governance issues.
• Market Sentiment: Their investment decisions can significantly impact the stock price, influencing market sentiment and attracting or deterring other investors.

Recent Moves

Monitoring recent transactions by key investors offers insights into their confidence in the company's prospects.

• Buying Activity: Large purchases by prominent investors can signal strong confidence in Akero Therapeutics, Inc. (AKRO)'s future, potentially driving the stock price up.
• Selling Activity: Conversely, significant sales by insiders or major shareholders might raise concerns about the company's prospects, leading to a potential decrease in stock value.
• Activist Interventions: Activist investors might propose specific changes to the company's strategy or operations to unlock value.

To get a clearer picture of investor activity, one can analyze:

• SEC Filings: Reviewing 13D filings, which are required when an investor acquires more than 5% of a company's shares, can provide insights into activist intentions.
• Earnings Calls and Investor Presentations: These events often provide clues about investor sentiment and management's interactions with key shareholders.
• News and Media: Keep an eye on financial news outlets for reports on significant investor moves or activist campaigns involving Akero Therapeutics, Inc. (AKRO).

Information on Akero Therapeutics, Inc. (AKRO)'s history, mission, ownership structure, and business model can be found at: Akero Therapeutics, Inc. (AKRO): History, Ownership, Mission, How It Works & Makes Money

Akero Therapeutics, Inc. (AKRO) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Akero Therapeutics, Inc. (AKRO) is crucial for assessing the company's current position and future prospects. Major shareholders' attitudes, market responses to ownership changes, and analyst perspectives all contribute to a comprehensive view of AKRO's financial health.

Currently, pinpointing the exact real-time sentiment of major shareholders towards Akero Therapeutics, Inc. requires up-to-the-minute data. However, monitoring significant institutional holdings and their trading activity can provide insight. An increase in holdings might suggest a positive outlook, while a decrease could indicate concerns. Examining the behavior of institutional investors, such as hedge funds and large investment firms, often signals the prevailing sentiment.

Recent market reactions to changes in ownership or large investor moves can significantly impact Akero Therapeutics, Inc.’s stock price. For example, a notable purchase by a well-known investment firm might drive the stock price up, reflecting increased confidence in the company's prospects. Conversely, a large sell-off could lead to a price decline. Monitoring these movements and their immediate effects on the stock is essential for understanding market confidence.

Analyst perspectives play a vital role in interpreting the potential impact of key investors on Akero Therapeutics, Inc.'s future. Analysts often provide insights on how major investment decisions could affect the company's strategy, financial performance, and overall outlook. These analyses can highlight potential risks and opportunities associated with significant investor activity, offering a balanced view of the company's trajectory.

To provide a clearer picture, consider the following aspects that influence investor sentiment and market reactions:

• Clinical Trial Results: Positive outcomes from clinical trials typically boost investor confidence, while setbacks can lead to negative sentiment.
• Regulatory Developments: FDA approvals or rejections significantly impact market perception.
• Financial Performance: Strong earnings reports and positive financial forecasts generally improve investor sentiment.
• Market Trends: Broader market trends and sector-specific dynamics can also influence how investors view Akero Therapeutics, Inc.

While specific, real-time data on investor sentiment changes rapidly, keeping track of these indicators provides a solid foundation for assessing Akero Therapeutics, Inc.'s market dynamics. For more insights into the company's core values and strategic direction, explore: Mission Statement, Vision, & Core Values of Akero Therapeutics, Inc. (AKRO).